Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis-Reference-Cited by-同舟云学术

Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis

Published:2024-09-13 Issue:1 Volume:24 Page:
ISSN:1471-2334
Container-title:BMC Infectious Diseases
language:en
Short-container-title:BMC Infect Dis

Author:

Zhan Yangyang,Mao Wenchao^ORCID,Zhao Changyun,Lu Difan,Chen Changqin,Hu Weihang,Yang Qi

Funder

Medical Science and Technology Project of Zhejiang Province

Key Construction Disciplines of Provincial and Municipal Co construction of Zhejiang

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12879-024-09899-5.pdf

Reference41 articles.

1. Coppola N, Maraolo AE, Onorato L, et al. Epidemiology, mechanisms of Resistance and Treatment Algorithm for infections due to Carbapenem-Resistant Gram-negative Bacteria: an Expert Panel Opinion. Antibiot (Basel). 2022;11(9):1263. https://doi.org/10.3390/antibiotics11091263.

2. Liu C, Chen K, Wu Y, et al. Epidemiological and genetic characteristics of clinical carbapenem-resistant Acinetobacter baumannii strains collected countrywide from hospital intensive care units (ICUs) in China. Emerg Microbes Infect. 2022;11(1):1730–41. https://doi.org/10.1080/22221751.2022.2093134.

3. Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400. https://doi.org/10.1016/S1473-3099(18)30099-9.

4. Dickstein Y, Lellouche J, Ben Dalak Amar M, AIDA Study Group, et al. Treatment outcomes of colistin- and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a Randomized Clinical Trial. Clin Infect Dis. 2019;69(5):769–76. https://doi.org/10.1093/cid/ciy988.

5. Shields RK, Paterson DL, Tamma PD. Navigating available treatment options for Carbapenem-Resistant Acinetobacter baumannii-Calcoaceticus Complex infections. Clin Infect Dis. 2023;76(Suppl 2):S179–93. https://doi.org/10.1093/cid/ciad094.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of multidrug-resistant gram-negative bacilli infections in adult solid organ transplant recipients: GESITRA-IC/SEIMC, CIBERINFEC, and SET recommendations update.;Transplantation Reviews;2025-07

2. Are cefiderocol or sulbactam/durlobactam better than alternative best available treatment for infection by carbapenem-resistant A. baumannii? A systematic literature review;Infection;2025-04-07

3. The challenges of difficult-to-treat Acinetobacter infections;Clinical Microbiology Reviews;2024-12-10

4. Treatment of Carbapenem-Resistant Acinetobacter baumannii in Real Life (T-ACI): A Prospective Single-Center Observational Study;Antibiotics;2024-10-25

5. Correction: Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis;BMC Infectious Diseases;2024-10-01